Background: Cardiovascular disease (CVD) is one of the leading causes of mortality around the world and in India as well. Atherosclerosis is the underlying cause in most of the cases. There are several modifiable (hypertension, diabetes mellitus, dyslipidemia, smoking, tobacco use, obesity and sedentary lifestyle) and non-modifiable (age, gender, family history of premature CVD, race, postmenopausal state) risk factors. The risk in Indians is around 3 to 4 times higher than in western countries, also CVD occurs 5 to 10 years earlier in Indians compared to western counterparts. The prevalence of diabetes mellitus in India is also one of the highest in the world and diabetes is the major risk factor for development of CVD. Methods: We analysed the clinical profile and in-hospital outcomes of 400 patients who presented with acute ST elevation myocardial infarction (STEMI) in a tertiary care centre in rural southern India. Results: d Majority of the patients were from the age group 51 to 60 years, followed by age group 61 to 70 years. MI in the age group 21 to 30 yrs was 3% and above 71 years was 2%. Background: Glycoprotein (Gp) IIbIIIa receptor inhibitors are known to reduce mortality, target vessel revascularization but not re-infarction in ST elevation myocardial
Conclusion: Mortality rate was higher in patients with IWMI + RVI. Only 15% reached the hospital within golden hour, more than half of the patients presented within 6 hours and men sought medical help earlier than women. Outcomes were favourable when patients received early thrombolytic therapy and those who presented within the golden hour had better resolution of symptoms and ECG changes post thrombolysis. Streptokinase is still a good and economical thrombolytic agent. Background: Glycoprotein (Gp) IIbIIIa receptor inhibitors are known to reduce mortality, target vessel revascularization but not re-infarction in ST elevation myocardial infarction (STEMI) patients. We investigated the impact of Gp IIbIIIa receptor inhibitors on the post procedure TIMI flow and 1 month major clinical outcomes in diabetic STEMI patients undergoing primary percutaneous coronary intervention (PCI). Methods: Total of 1562 diabetic STEMI patients undergoing primary PCI with or without periprocedural Gp IIbIIIa receptor inhibitor coverage were identified from Korean AMI registry (KAMIR). Among 1562 patients, 1107 patients didn't receive periprocedural GP IIbIIIa receptor inhibitors and 365 patients received. Results: Baseline characteristics were balanced between the two groups except for gender and the incidence of ischemic heart disease. There was no significant impact of GPIIbIIIa receptor inhibitor on the post procedure TIMI flow and 1month major clinical outcomes (Table) . Among no Gp IIbIIIa receptor inhibitor usage patients, 80.3% achieved TIMI III flow and 81.6% in the Gp IIbIIIa receptor inhibitor usage. Conclusion: Although the Gp IIbIIIa receptor inhibitor is known to reduce mortality and target vessel revascularization in STEMI patients, there was no statistically significant impact on the post procedural TIMI flow and 1month major clinical outcomes in diabetic STEMI patients undergoing primary PCI.
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Impact of Percutaneous Coronary Intervention on 12-month Chronic Total Occlusion Outcomes in Patients with Myocardial Infarction
Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Yoonjee Park, Akkala Raghavender Goud, Hu Li, Sunki Lee, Ji Bak Kim, Sung Il Im, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh Korea University Guro Hospital, Seoul, Korea (Republic of) Background: Myocardial infarction (MI) is known to be associated with increased adverse clinical outcomes in coronary artery diseases. The impact of percutaneous coronary intervention (PCI) for CTO in patients with myocardial infarction is not clear. We evaluated the 12-month clinical outcomes between PCI and optimal medical therapy (OMT) for CTO lesions in MI patients. Methods: A total of 143 consecutive CTO patients who were admitted for MI were divided into 2 groups according to treatment strategy; PCI group (n¼68) and OMT group (n¼75). 12-month clinical outcomes were compared between the two groups. Results: At baseline, patients in the OMT group showed a higher prevalence of elderly, hyperlipidemia, peripheral vascular disease, de novo lesion, non-CTO procedure, multivessel disease, and LCX-CTO. Patients in the PCI group showed a higher prevalence of prior MI, prior PTCA, and LAD-CTO lesion. Clinical outcomes at 12 months showed lower mortality and lower rates of recurrent MI in the PCI group. After baseline adjustment by multivariate analysis, however, there was no difference. Conclusion: At baseline, patients in the OMT group showed a higher prevalence of elderly, hyperlipidemia, peripheral vascular disease, de novo lesion, non-CTO procedure, multivessel disease, and LCX-CTO. Patients in the PCI group showed a higher prevalence of prior MI, prior PTCA, and LAD-CTO lesion. Clinical outcomes at 12 months showed lower mortality and lower rates of recurrent MI in the PCI group. After baseline adjustment by multivariate analysis, however, there was no difference.
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